1

We do not know. Until there is a phase 3 clinical trial and ivermectin gets FDA approval, it is too early to draw definite conclusions. The NIH has gathered all studies performed and combined them into a table. All of them have methodical disadvantages and limitations such as no peer review, no randomisation or a small sample size (20 patients in each arm) ...


Only top voted, non community-wiki answers of a minimum length are eligible